TY - JOUR T1 - Introduction into the Marseille geographical area of a mild SARS-CoV-2 variant originating from sub-Saharan Africa JF - medRxiv DO - 10.1101/2020.12.23.20248758 SP - 2020.12.23.20248758 AU - Philippe Colson AU - Anthony Levasseur AU - Philippe Gautret AU - Florence Fenollar AU - Van Thuan Hoang AU - Jeremy Delerce AU - Idir Bitam AU - Rachid Saile AU - Mossaab Maaloum AU - Abdou Padane AU - Marielle Bedotto AU - Ludivine Brechard AU - Vincent Bossi AU - Mariem Ben Khedher AU - Hervé Chaudet AU - Matthieu Million AU - Hervé Tissot-Dupont AU - Jean-Christophe Lagier AU - Souleymane Mboup AU - Pierre-Edouard Fournier AU - Didier Raoult Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/12/24/2020.12.23.20248758.abstract N2 - BACKGROUND In Marseille, France, the COVID-19 incidence evolved unusually with several successive epidemic episodes. The second outbreak started in July, was associated with North Africa, and involved travelers and an outbreak on passenger ships. This suggested the involvement of a new viral variant.METHODS We sequenced the genomes from 916 SARS-CoV-2 strains from COVID-19 patients in our institute. The patients’ demographic and clinical features were compared according to the infecting viral variant.RESULTS From June 26th to August 14th, we identified a new viral variant (Marseille-1). Based on genome sequences (n=89) or specific qPCR (n=53), 142 patients infected with this variant were detected. It is characterized by a combination of 10 mutations located in the nsp2, nsp3, nsp12, S, ORF3a, ORF8 and N/ORF14 genes. We identified Senegal and Gambia, where the virus had been transferred from China and Europe in February-April as the sources of the Marseille-1 variant, which then most likely reached Marseille through Maghreb when French borders reopened. In France, this variant apparently remained almost limited to Marseille. In addition, it was significantly associated with a milder disease compared to clade 20A ancestor strains.CONCLUSION Our results demonstrate that SARS-CoV-2 can genetically diversify rapidly, its variants can diffuse internationally and cause successive outbreaks.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the French Government under the Investments for the Future programme managed by the National Agency for Research (ANR), Mediterranee-Infection 10-IAHU-03 and was also supported by Region Provence Alpes Cote d'Azur and European funding FEDER PRIMMI (Fonds Europeen de Developpement Regional-Plateformes de Recherche et d'Innovation Mutualisees Mediterranee Infection), FEDER PA 0000320 PRIMMI.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the ethical committee of the Mediterranee Infection Institute (2020-016-2). Access to the patients' biological and registry data issued from the hospital information system was approved by the data protection committee of Assistance Publique-Hopitaux de Marseille (APHM) and was recorded in the European General Data Protection Regulation registry under number RGPD/APHM 2019-73All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in the present manuscript are available upon request ER -